Compare Eastern Bankshares Inc. Common Stock (EBC) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eastern Bankshares Inc. Common Stock vs TG Therapeutics Inc — how do they compare? Eastern Bankshares Inc. Common Stock trades at $20.77 (market cap $4.76B), while TG Therapeutics Inc trades at $54.13 (market cap $8.32B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and Eastern Bankshares Inc. Common Stock pays a 2.69% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eastern Bankshares Inc. Common Stock for 0 Days and TG Therapeutics Inc for 16 Days on average.
| EBC | TGTX | |
|---|---|---|
Market Cap | $4.76B | $8.32B |
Volume | 2,941,879 | 1,285,303 |
Sector | Financials | Health |
52-Week High | $23.65 | $59.06 |
52-Week Low | $16.73 | $26.94 |
Typical Hold Time | 0 Days | 16 Days |
Enterprise Value | $4.98B | $8.52B |
Dividend Yield | 2.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eastern Bankshares (EBC) trades at $20.96, down 0.85% on the day, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.71, net income margin of 33.47%, and recent Q2 2026 EPS beat. Analyst consensus is bullish with a $25.60 price target. Recent news highlights institutional buying and upcoming Q3 2026 earnings.
The outlook is positive given solid profitability, attractive valuation, and analyst support. Key risks include integration challenges from recent acquisitions and interest rate sensitivity. Upside potential exists if earnings momentum continues, but investors should monitor net cash flow trends and competitive pressures.
TG Therapeutics (TGTX) trades at $54.34, down 1.68% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong revenue growth, with 2025 revenue at $616.29 million and net income of $447.18 million, though recent quarterly EPS results missed expectations. Analyst sentiment is overwhelmingly positive, with 11 buy ratings and a consensus price target of $80.50, while recent news highlights Briumvi's market share gains and potential acquisition interest.
The outlook for TGTX is favorable, driven by Briumvi's expanding multiple sclerosis market share and raised 2026 revenue guidance to $950 million. Key risks include ongoing earnings misses, a high EV/EBITDA ratio of 61.15, and a shareholder litigation investigation. Upside potential remains if the company meets future earnings targets and sustains its growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Eastern Bankshares Inc. Common Stock
Eastern Bankshares, Inc. is the holding company for Eastern Bank, a Massachusetts-based bank operating more than 125 branches across eastern Massachusetts, southern and coastal New Hampshire, and Rhode Island, offering consumer and business banking along with wealth management through its Cambridge Trust divisions.
Read more on EBC →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
